Accumulated evidence indicates that EC-specific inhibition of NF-κB is beneficial in many pathological settings, including protection from atherosclerosis (66), enhancing functional hematopoiesis (67), and attenuating hypertension-induced renal damage (68). The gene discussed is NFKB1; the disease is Hypertension.